Amarin reported $12.54M in EBITDA for its fiscal quarter ending in June of 2025.





Ebitda Change Date
AbbVie USD 3.52B 828M Sep/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amarin USD 12.54M 28.57M Jun/2025
AstraZeneca USD 5.23B 272M Sep/2025
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
DBV Technologies USD -33.48M 5.55M Sep/2025
Esperion Therapeutics USD -9.93M 24.99M Sep/2025
GlaxoSmithKline GBP 3.36B 179M Sep/2025
Halozyme Therapeutics USD 21.9M 226.34M Dec/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Neurocrine Biosciences USD 218.4M 28.3M Dec/2025
Novartis USD 5.88B 290M Sep/2025